http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20210058590-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_95363fc2cf0b49e7a4aef32d7cb692a1 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-551 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4985 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4985 |
| filingDate | 2019-11-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2b74cf4f5e6954cf207232b4ec434324 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1e1cc35fdf9cd21dc2a1d964f688eb0f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_058e2aa2a3958641c6db5b94ff8a73a1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_86088b7f9a71e9d6fa751d183999e8d1 |
| publicationDate | 2021-05-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20210058590-A |
| titleOfInvention | A pharmaceutical composition for treating loss of locomotor activity due to stroke containing sildenafil and Rho-associasted kinase inhibitor |
| abstract | The present invention relates to a pharmaceutical composition for the treatment of sequelae due to ischemic cerebrovascular disease comprising a phosphodiesterase type 5 activity inhibitor (phosphodiesterase type 5 inhibitor) and a ROCK inhibitor (Rho-associasted kinase inhibitor), and more specifically It relates to a pharmaceutical composition for treating loss of motor function due to stroke, comprising sildenafil and GSK429286A. The present inventors studied to use sildenafil and a ROCK inhibitor in combination in the treatment of sequelae due to stroke based on clinical knowledge related to stroke treatment.As a result, sildenafil and a ROCK inhibitor were used in combination compared to the case where sildenafil and a ROCK inhibitor were respectively administered alone. When administered, it was confirmed for the first time that the loss of motor function due to stroke was significantly improved.The pharmaceutical composition according to the present invention is expected to be useful in the treatment or research of sequelae related to motor function caused by stroke. do. |
| priorityDate | 2019-11-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 68.